UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 26, 2011

---

                                                                                                                                                        

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Nevada (State or other jurisdiction of incorporation)

000-21846 (Commission File Number)

13-3632859 (I.R.S. Employer Identification No.)

 

8910 University Center Lane, Suite 660 San Diego, California (Address of principal executive offices)

92122 (Zip Code)

 

Registrant’s telephone number, including area code:  (858) 459-7800

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

 

Item 7.01                      Regulation FD Disclosure

 

The Registrant disclosed that on Thursday, May 26, 2011, it made a presentation at the C21 BioVentures Drug Partnering Conference in Napa, California.  A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01.  Also, the Registrant posted the investor presentation materials to its website (www.aethlonmedical.com) today, May 31, 2011.

Item 9.01                      Financial Statements and Exhibits.

   

(d)           Exhibits.  The following exhibit is being furnished pursuant to Item 7.01 above.

 

	Exhibit No.		Description
	99.1		Aethlon C21 Presentation 05-26-11

 

 

 

 

 

---

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	AETHLON MEDICAL, INC.
	(Registrant)
Date: May 31, 2011	By:	/s/ James B. Frakes
		James B. Frakes
		Chief Financial Officer

 

 

 

 

 

---

 

 

EXHIBIT INDEX

 

 

Exhibit No.		Description
99.1		Presentation Materials

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4